Appendix 5

Supplementary Table S2. Sensitivity analysis comparing admissions with versus without concurrent paediatric inflammatory multisystem syndrome (PIMS).

| Characteristics, n (%) ¹ | All Cases ² | All Cases, PIMS excluded |
|---|------------------------|--------------------------|
| Admissions attributable to COVID-19, N | 150 | 135 |
| Age of child ³ | | |
| Infants (<1 year) | 63 (42.3) | 62 (46.3) |
| Preschool (1-5 years) | 23 (15.4) | 21 (15.7) |
| School age (6-12 years) | 27 (18.1) | 21 (15.7) |
| Adolescents (13-17 years) | 36 (24.2) | 30 (22.4) |
| Any comorbid condition | 59 (39.3) | 54 (40.0) |
| Clinical presentation ⁴ | | |
| Non-severe | 75 (50.0) | 71 (52.6) |
| Severe | 75 (50.0) | 64 (47.4) |
| Respiratory or hemodynamic support required | 42 (28.0) | 32 (23.7) |
| Intensive care required | 32 (21.3) | 23 (17.0) |
| Select complications | | |
| Pneumonia | 26-29 (17.3-19.3) | 24 (17.8) |
| Coagulopathy | 15-18 (10.0-12.0) | 11 (8.1) |
| Hepatitis | 16-19 (10.7-12.7) | 9 (6.7) |
| Hypotension | 17 (11.3) | 8 (5.9) |
| Renal dysfunction | 12 (8.0) | 8 (5.9) |
| Cytokine storm/Macrophage activating syndrome | 10 (6.7) | <5 (<3.7) |
| Acute respiratory distress syndrome | 9-12 (6.0-8.0) | <5 (<3.7) |
| Treatments received | | |
| Antibiotics (e.g. ceftriaxone) | 81 (54.0) | 69 (51.1) |
| Steroids | 33-36 (22.0-24.0) | 25 (18.5) |
| Immunoglobulin (IV) | 16-19 (10.7-12.7) | 5 (3.7) |
| Bronchodilators | 15-18 (10.0-12.0) | 16 (11.9) |
| Anticoagulation | 12-15 (8.0-10.0) | 7 (5.2) |
| ASA | 9-12 (6.0-8.0) | <5 (<3.7) |
| Azithromycin | 9 (6.0) | 7 (5.2) |

¹Percentages were calculated as those known to have experienced a clinical feature, divided by all admissions in the column total.

References

1. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145:e20200702.

Appendix 5, as supplied by the authors. Appendix to: Drouin O, Moore Hepburn C, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada. *CMAJ* 2021. doi: 10.1503/cmaj.210053. Copyright © 2021 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

²Some statistics are presented as ranges to prevent back-calculation of cells in conjunction with Tables 2 and 5.

³Age was unknown for one child overall.

⁴Defined using criteria modified from Dong et al. (2020). Non-severe disease combines mild, and moderate illness; severe disease combines severe and critical illness.